Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Death in Lebanon

 
The Ministry of Public Health launched in collaboration with the national committee for the prevention of cardiovascular diseases and Yaduna -Women Heart Health Center the National campaign for the early detection and prevention of cardiovascular diseases under the title “Don’t wait, your heart can’t wait”, during a conference held under the patronage and in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani at the Adnan Kassar Edifice in Bir Hassan.
 
The Head of Primary health care Department at Health Ministry Dr. Randa Hamadeh made a presentation of the path of the national campaign. “This campaign that starts today will last for three months until the end of April. It will kick off from the national network of primary health care centers located across all the Lebanese territory and aims at providing services to citizens, i.e. free cardiovascular examinations for men and women,”Dr. Hamadeh added.
 
The Chairperson of Yaduna foundation Wafaa Sleiman delivered a statement in which she noted that the increasing number of women who underwent an early testing at the Women Heart Health Center, and the detection of many cases of cardiovascular diseases contributed greatly in the treatment of these cases, and led us to activate the prevention and awareness actions across all the Lebanese territory.
 
Hasbani

In a statement, Hasbani noted that the non-communicable diseases cause the death of 38 million people each year, 28 million death cases of which occur in low- and middle-income countries.

“Non-communicable diseases threaten the progress towards achieving the Millennium Development Goals. Poverty and such diseases are highly correlated and it is expected that the rapid growth of these diseases hinder poverty alleviation initiatives in low-income countries, in particular by increasing household costs associated with healthcare services,” Hasbani added.
 
Hasbani highlighted that this activity complements all these efforts, especially that it is integrated with that of Yaduna - Women Heart Health Center, knowing that the primary healthcare brings together all sectors to provide best services to citizens.(Read more...)
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
A05AA04 OCALIVA B Obeticholic acid - 10mg 10mg Tablet, film coated 224,503,943 L.L
A05AA04 OCALIVA B Obeticholic acid - 5mg 5mg Tablet, film coated 224,503,943 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 920mg/23ml 920mg/23ml Injectable solution 1,095,034,629 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 2.5g/50ml Injectable solution 19,540,934 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution 37,672,334 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 10g/200ml Injectable solution 74,515,099 L.L
J06BA02 OCTAGAM 10% BioHuman Human normal immunoglobulin G - 10% 5g/50ml Injectable solution 37,672,334 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 13,247,110 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 26,495,478 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 1,000IU 1,000IU Injectable lyophilised powder for solution+diluent 46,817,511 L.L
B02BD04 OCTANINE F BioHuman Plasma coagulation factor IX, human - 500IU 500IU Injectable freeze dried powder + diluent 31,425,075 L.L
B02BD01 OCTAPLEX BioHuman Prothrombin complex, human (PPSB) - 500IU 500IU Injectable powder for solution+diluent 35,220,164 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 4mg/2ml 4mg/2ml Injectable solution 880,217 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 8mg/4ml 8mg/4ml Injectable solution 952,784 L.L
G03CA03 OESTRACLIN G Estradiol - 0.6mg/g 0.6mg/g Gel 448,843 L.L
G03CA03 OESTRODOSE B Estradiol (17 bêta estradiol anhydre) - 0.06% 0.06% Gel 642,357 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft L.L
L01EX09 OFEV B Nintedanib - 100mg 100mg Capsule, soft 104,970,427 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft 209,943,960 L.L
J01MA01 OFLACIN G Ofloxacin - 200mg 200mg Tablet, film-scored 602,041 L.L
J01MA01 OFLOMED G Ofloxacin - 200mg 200mg Tablet, film-scored 601,530 L.L
S02AA16 OFLOMED G Ofloxacin - 3mg/ml 3mg/ml Drops solution 317,403 L.L
S01AE01 OFLOX B Ofloxacin - 3mg/ml 0.3% Drops solution 366,869 L.L
S01AE01 OFLOX B Ofloxacin - 0.3% 0.3% Drops solution 366,869 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
N05AH03 OLANZAMED G Olanzapine - 20mg 20mg Tablet 3,941,938 L.L
N05AH03 OLANZAMED G Olanzapine - 10mg 10mg Tablet 902,294 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026